Valneva SE - Asset Resilience Ratio
Valneva SE (VLA) has an Asset Resilience Ratio of 0.03% as of September 2020. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See VLA working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2005–2014)
This chart shows how Valneva SE's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see VLA current and non-current assets.
Liquid Assets Composition Over Time
This chart breaks down Valneva SE's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore VLA long-term investments to assets to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €150.00K | 0.03% |
| Total Liquid Assets | €150.00K | 0.03% |
Asset Resilience Insights
- Limited Liquidity: Valneva SE maintains only 0.03% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Valneva SE Industry Peers by Asset Resilience Ratio
Compare Valneva SE's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH |
Biotechnology | 33.23% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 65.12% |
Annual Asset Resilience Ratio for Valneva SE (2005–2014)
The table below shows the annual Asset Resilience Ratio data for Valneva SE.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2014-12-31 | 0.01% | €19.00K ≈ $22.21K |
€227.52 Million ≈ $265.99 Million |
-1.43pp |
| 2013-12-31 | 1.44% | €3.66 Million ≈ $4.28 Million |
€254.39 Million ≈ $297.41 Million |
-19.48pp |
| 2012-12-31 | 20.92% | €11.22 Million ≈ $13.12 Million |
€53.67 Million ≈ $62.74 Million |
-7.34pp |
| 2011-12-31 | 28.25% | €20.65 Million ≈ $24.14 Million |
€73.08 Million ≈ $85.44 Million |
+18.50pp |
| 2010-12-31 | 9.75% | €7.75 Million ≈ $9.07 Million |
€79.50 Million ≈ $92.94 Million |
+0.06pp |
| 2008-12-31 | 9.70% | €4.01 Million ≈ $4.69 Million |
€41.38 Million ≈ $48.38 Million |
-19.50pp |
| 2007-12-31 | 29.20% | €11.56 Million ≈ $13.51 Million |
€39.58 Million ≈ $46.28 Million |
+17.93pp |
| 2006-12-31 | 11.27% | €1.68 Million ≈ $1.97 Million |
€14.92 Million ≈ $17.45 Million |
-11.83pp |
| 2005-12-31 | 23.10% | €3.37 Million ≈ $3.94 Million |
€14.60 Million ≈ $17.07 Million |
-- |
About Valneva SE
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile t… Read more